OncoMatch/Clinical Trials/NCT04922567
Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma
Is NCT04922567 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for peripheral t-cell lymphoma.
Treatment: Lenalidomide · Cyclophosphamide · Doxorubicin · Vincristine · Prednisone — This study aims to compare the efficacy and safety of lenalidomide plus CHOP (L-CHOP) versus CHOP alone in patients with previously untreated peripheral T-cell lymphoma (PTCL)
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: any anti-tumor therapy
Exception: prephase treatment specified for this study
Lab requirements
Blood counts
absolute neutrophil count(ANC)≥1.5×10^9/L, hemoglobin(Hb)≥90g/L, platelet(PLT)≥100×10^12/L
Kidney function
creatine ≤2.0×ULN
Liver function
total bilirubin ≤2.0mg/dl, transaminases≤3×ULN
Cardiac function
no obvious abnormal function of heart; decompensated heart failure, dilated cardiomyopathy, coronary heart disease of non-corresponding ST-segment in ECG diagnosis, or myocardial infarction within 6 months excluded
Fit chemotherapy indications and basic requirements, including no obvious abnormal function of heart, liver, lung and kidney: creatine ≤2.0×ULN, total bilirubin ≤2.0mg/dl, transaminases≤3×ULN. Normal peripheral hemogram: absolute neutrophil count(ANC)≥1.5×10^9/L, hemoglobin(Hb)≥90g/L, platelet(PLT)≥100×10^12/L. Hemogram abnormality: ANC<1.5×10^9/L; or hemoglobin<90 g/L; or PLT<100×10^9/L. Known hepatic and renal insufficiency (creatine>2.0×ULN, total bilirubin>2.0 mg/dl，transaminases>3.0×ULN). Patients with decompensated heart failure; or with dilated cardiomyopathy; or with coronary heart disease of non-corresponding ST-segment in ECG diagnosis; or with myocardial infarction within 6 months.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify